This invention relates to antibodies with altered binding to FcRn, andparticularly antibodies having enhancedbinding to FcRn and/or enhanced serum half-lives. The invention also relatesto methods of using the antibodies and compositionscomprising them in the diagnosis, prognosis and therapy of diseases such ascancer, autoimmune diseases, inflammatory disorders,and infectious disease.